GT Biopharma
GTBP | NASDAQ
$3.54
-$0.18 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$3.61
+$0.07 (+1.98%)
After-hours:
Nov 16, 2026, 6:41 PM ET
-4.84%
(1D)No price chart data available for 1D timeframe.
Rating
25
-1.5 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #929/1021 (Top 91%)
Key Statistics
Market Data
Market Cap $5.5M
1D Range
3.45 3.90
52W Range
3.45 23.00
Valuation (TTM)
PE -0.03
PB 1.54
EV/EBITDA -0.03
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -262.4%
SBC Adj. FCF Yield -278.9%
SBC Impact -6.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 32.9% |
32.1%
FCF 3Y | 5Y -11.1% |
3.1%
Returns
ROA -381.5%
ROE -443.1%
ROIC -457.8%
Financial Health
Net Cash
$4.96M
Current Ratio 2.61
Interest Coverage -128.64
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers...
Sector Healthcare
Industry Biotechnology
Employees 1
IPO Date Mar 27, 2018
Website www.gtbiopharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove GTBP